A multicentre, randomised, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of BP1.4979 in adult patients with essential tremor

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517987-46-00

Acronym

P23-05

Enrollment

Registered

2025-06-13

Start date

2025-07-21

Completion date

Unknown

Last updated

2025-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential tremor

Brief summary

The primary efficacy endpoint is the change in the total score of the Performance Subscale of The Essential Tremor Rating Assessment Scale (TETRAS-P) after 4 weeks of treatment.

Detailed description

No secondary endpoints are planned in this trial.

Interventions

DRUGMatches test product

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The primary efficacy endpoint is the change in the total score of the Performance Subscale of The Essential Tremor Rating Assessment Scale (TETRAS-P) after 4 weeks of treatment.	—

Secondary

Measure	Time frame
No secondary endpoints are planned in this trial.	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026